Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early efficacy heterogeneity of ivarmacitinib in atopic dermatitis
ChiCTR2600133438Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivarmacitinib in atopic dermatitis (AD) (3 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Week 12 EASI-75 response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600133438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133438.